Stockreport

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit ...

Jazz Pharmaceuticals plc - Ordinary Shares  (JAZZ) 
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: jazzpharma.com
PDF chemotherapy to replace trastuzumab as the new standard of care, with or without tislelizumab regardless of PD-L1 status Late-breaking results to be presented at the 2 [Read more]